Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more
Cardiol Therapeutics Inc Class A (CRDL) - Net Assets
Latest net assets as of September 2025: $9.56 Million USD
Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has net assets worth $9.56 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.95 Million) and total liabilities ($3.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.56 Million |
| % of Total Assets | 73.84% |
| Annual Growth Rate | 36.13% |
| 5-Year Change | 86.34% |
| 10-Year Change | N/A |
| Growth Volatility | 278.61 |
Cardiol Therapeutics Inc Class A - Net Assets Trend (2017–2024)
This chart illustrates how Cardiol Therapeutics Inc Class A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cardiol Therapeutics Inc Class A (2017–2024)
The table below shows the annual net assets of Cardiol Therapeutics Inc Class A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $24.73 Million | -12.45% |
| 2023-12-31 | $28.25 Million | -26.65% |
| 2022-12-31 | $38.51 Million | -49.49% |
| 2021-12-31 | $76.24 Million | +474.50% |
| 2020-12-31 | $13.27 Million | -9.55% |
| 2019-12-31 | $14.67 Million | -34.13% |
| 2018-12-31 | $22.27 Million | +680.47% |
| 2017-12-31 | $2.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cardiol Therapeutics Inc Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17759317500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $179.34 Million | 725.22% |
| Other Components | $24.65 Million | 99.67% |
| Total Equity | $24.73 Million | 100.00% |
Cardiol Therapeutics Inc Class A Competitors by Market Cap
The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
$74.36 Million |
|
Sitowise Group Oyj
HE:SITOWS
|
$74.38 Million |
|
EVe Mobility Acquisition Corp
NYSE MKT:EVE
|
$74.38 Million |
|
Questerre Energy Corporation
PINK:QTEYF
|
$74.39 Million |
|
FULL HOUSE RES DL-0001
F:F4L
|
$74.33 Million |
|
SHOPER SPOL.A.A-C ZY 010
F:8FF
|
$74.31 Million |
|
Bank of the James Financial Group
NASDAQ:BOTJ
|
$74.30 Million |
|
Empresas Tricot S.A
SN:TRICOT
|
$74.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cardiol Therapeutics Inc Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 28,246,507 to 24,728,483, a change of -3,518,024 (-12.5%).
- Net loss of 36,677,299 reduced equity.
- New share issuances of 21,355,588 increased equity.
- Other comprehensive income decreased equity by 3,517,867.
- Other factors increased equity by 15,321,554.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.68 Million | -148.32% |
| Share Issuances | $21.36 Million | +86.36% |
| Other Comprehensive Income | $-3.52 Million | -14.23% |
| Other Changes | $15.32 Million | +61.96% |
| Total Change | $- | -12.45% |
Book Value vs Market Value Analysis
This analysis compares Cardiol Therapeutics Inc Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.85x to 2.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.13 | $0.99 | x |
| 2018-12-31 | $0.92 | $0.99 | x |
| 2019-12-31 | $0.57 | $0.99 | x |
| 2020-12-31 | $0.44 | $0.99 | x |
| 2021-12-31 | $1.76 | $0.99 | x |
| 2022-12-31 | $0.62 | $0.99 | x |
| 2023-12-31 | $0.44 | $0.99 | x |
| 2024-12-31 | $0.35 | $0.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cardiol Therapeutics Inc Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -148.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-148.32%) is below the historical average (-79.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -58.20% | 0.00% | 0.00x | 1.13x | $-1.95 Million |
| 2018 | -71.36% | 0.00% | 0.00x | 1.11x | $-18.12 Million |
| 2019 | -71.92% | 0.00% | 0.00x | 1.06x | $-12.02 Million |
| 2020 | -122.09% | -20570.94% | 0.00x | 1.20x | $-17.53 Million |
| 2021 | -32.81% | -40170.87% | 0.00x | 1.15x | $-32.64 Million |
| 2022 | -59.25% | 0.00% | 0.00x | 1.19x | $-26.67 Million |
| 2023 | -75.13% | 0.00% | 0.00x | 1.30x | $-24.05 Million |
| 2024 | -148.32% | 0.00% | 0.00x | 1.29x | $-39.15 Million |
Industry Comparison
This section compares Cardiol Therapeutics Inc Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cardiol Therapeutics Inc Class A (CRDL) | $9.56 Million | -58.20% | 0.35x | $74.34 Million |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |